JEVTANA (cabazitaxel) 60mg
| Product Overview | |
| Generic Name | JEVTANA (cabazitaxel) 60mg |
| Brand Name(s) | Jevtana |
| Product Type | Originator Brand |
| Form | lyophilized IV powder |
| Strength | 60 mg / 1.5 mL |
| Therapeutic Class | Antineoplastic, antimicrotubular taxane |
| ATC Code | L01CD04 |
| Manufacturing & Regulatory | |
| Manufacturer | Sanofi |
| Country | Canada, USA, India |
| GMP Compliance | WHO/EMA |
| DMF/CEP | #201023 |
| COFEPRIS | 010.000.5658.00 |
| Free Sale Certificate | Available from manufacturer/exporter upon request |
| Logistics & Export | |
| MOQ | 4 vials |
| Shelf Life | 24 months |
| Storage | 2–8 °C |
| Incoterms | EXW, HSN 30049099 |
| Lead Time | 7 to 10 Days |
| Documentation | |
| Certificate of Analysis (COA) | Yes |
| SDS | Upon Request |
| CTD Summary | CTD available to regulators; summary available to qualified partners |
Description
JEVTANA (cabazitaxel) is a chemotherapeutic agent indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have previously undergone a docetaxel-containing regimen. It functions by inhibiting microtubule disassembly, thereby disrupting cancer cell division and proliferation.
